Healthcare Sector
Market Tracker
Represents the strikes that had the highest premium of whale flow (on the ASK side) over the past 5 trading days.
Represents the strikes that had the highest premium of whale flow (on the BID side) over the past 5 trading days.
Total Open Interest of Calls & Puts across all strikes and expirations over the past 16 trading days.
| Expires | Type | Strike | OI | Change | Percent |
|---|---|---|---|---|---|
| 07/02/2026 | CALL | $24.50 | 10,063 | +4,535 | +82.04% |
| 07/02/2026 | CALL | $25.00 | 9,648 | +3,931 | +68.76% |
| 07/02/2026 | PUT | $24.00 | 4,851 | +2,719 | +127.53% |
| 09/18/2026 | CALL | $26.00 | 24,123 | +1,665 | +7.41% |
| 07/31/2026 | CALL | $25.00 | 3,366 | +1,557 | +86.07% |
| 07/10/2026 | CALL | $25.00 | 4,174 | +1,413 | +51.18% |
| 08/21/2026 | CALL | $29.00 | 2,510 | -106 | -4.05% |
| 07/10/2026 | CALL | $26.00 | 3,461 | -110 | -3.08% |
| 09/18/2026 | CALL | $30.00 | 28,743 | -293 | -1.01% |
| 07/17/2026 | CALL | $27.00 | 17,320 | -375 | -2.12% |
| 07/02/2026 | PUT | $26.00 | 342 | -739 | -68.36% |
| 09/18/2026 | CALL | $29.00 | 23,004 | -1,479 | -6.04% |
Contracts with largest changes in open interest from the previous trading day to the current/most recent.
| Name | Pct Held | Shares | Total |
|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.94% | 165.24M | 7.61B |
| Vanguard 500 Index Fund | 2.21% | 124.19M | 5.72B |
| Washington Mutual Investors Fund | 1.35% | 76.03M | 3.5B |
| Income Fund of America Inc | 1.13% | 63.51M | 2.92B |
| SPDR S&P 500 ETF Trust | 1.07% | 60.16M | 2.77B |
| Fidelity 500 Index Fund | 1.06% | 59.56M | 2.74B |
| American Balanced Fund | 1.06% | 59.6M | 2.74B |
| Vanguard Specialized-Health Care Fund | 0.99% | 55.6M | 2.56B |
| iShares Core S&P 500 ETF | 0.89% | 49.69M | 2.29B |
| Vanguard Index-Value Index Fund | 0.86% | 48.52M | 2.23B |
| Vanguard Institutional Index Fund-Institutional Index Fund | 0.74% | 41.57M | 1.91B |
| Vanguard/Wellington Fund Inc. | 0.64% | 36.07M | 1.66B |
| Vanguard Fenway Funds-Equity Income Fund | 0.58% | 32.43M | 1.49B |
| MFS Series Trust I-MFS Value Fund | 0.53% | 29.66M | 1.37B |
| Fundamental Investors Inc | 0.48% | 27.19M | 1.25B |
Big Pharma Has a Case of Merger Mania
06/30 12:26 am
The Motley Fool
Read moreAbbVie Stock Hits a New 52-Week High. Has It Gotten Too Expensive to Buy?
06/29 11:21 am
The Motley Fool
Read moreA CFO Departure. A Clinical Miss. A $43 Billion Question Mark. Should You Throw in the Towel on Pfizer Stock?
06/28 04:30 am
The Motley Fool
Read moreOpinion: Pfizer Is a Fantastic Dividend Stock for Income Investors to Buy Right Now
06/27 03:15 pm
The Motley Fool
Read moreAn Analyst Just Declared Eli Lilly the "Clear Winner" of an American Diabetes Association Conference Focused on Weight-Loss Drugs. Novo's Chief Scientist Disagrees. Who's Right?
06/25 11:18 am
The Motley Fool
Read moreOblenio Bio Closes $62 Million Series B to Advance Tri-specific T-Cell Engager LBL-051 for Autoimmune Diseases into Clinical Development
06/25 06:00 am
GlobeNewswire Inc.
Read more2 High-Yield Dividend Stocks to Buy and Hold for a Decade
06/23 04:30 pm
The Motley Fool
Read moreCould Pfizer Stock Be Your Ticket to Generational Wealth?
06/21 09:15 pm
The Motley Fool
Read moreWant to Retire on $500,000? 3 Stocks to Buy and Never Sell
06/21 04:24 am
The Motley Fool
Read morePfizer's Dividend Yield is 10X Bigger Than Eli Lilly's. Does That Make It the Better Stock for Income Investors?
06/20 05:15 pm
The Motley Fool
Read moreStock Market Today, June 18: Pfizer Falls as CFO Transition Tests Confidence in 2026 Outlook
06/18 07:09 pm
The Motley Fool
Read moreFDA Expands Merck Pneumococcal Shot Label To Include At-Risk Children And Teens
06/18 11:29 am
Benzinga
Read moreBio Usawa Appoints Dr. Aida Habtezion, Former Chief Medical Officer at Pfizer, to its Board of Directors
06/15 04:00 am
GlobeNewswire Inc.
Read moreHow Safe is Bristol Myers Squibb's Dividend? Here's My Honest Take.
06/13 06:15 pm
The Motley Fool
Read morePfizer's New Weight-Loss Data Just Gave Eli Lilly and Novo Nordisk Investors Something to Worry About
06/12 12:32 pm
The Motley Fool
Read moreValue Investors Question SpaceX's Record IPO: 'It's The Future That Kills You'
06/12 10:57 am
Benzinga
Read moreBristol Myers Squibb Dividend Raise Streak is 18 Years. Here's 1 Number That Says the Streak Will Continue.
06/11 02:02 pm
The Motley Fool
Read morePatent Cliff Predators: GSK Acquires Nuvalent For $10.6 Billion
06/11 01:18 pm
Investing.com
Read moreMetastatic Prostate Cancer Market Set for Robust Growth Through 2036, Driven by The Emergence of PARP Inhibitors and PSMA-targeted Radioligand Therapies | DelveInsight
06/10 01:00 pm
GlobeNewswire Inc.
Read morePfizer's Obesity Drug Shows 16% Weight Loss In Phase 2b Study
06/08 02:06 pm
Benzinga
Read more3 Dividend Stocks to Buy Hand Over Fist in June
06/07 01:30 am
The Motley Fool
Read moreCan Pfizer's Dividend Survive the Patent Cliff? This $10.5 Billion Cancer Bet Could Hold the Answer.
06/06 01:32 pm
The Motley Fool
Read morePfizer's 6.7% Yield Looks Scary -- but the Dividend Story Is Stronger Than It Seems
06/06 12:15 pm
The Motley Fool
Read moreArvinas Joins The Michael J. Fox Foundation’s LITE and PPMI Programs to Advance New Therapies Targeting LRRK2 for Parkinson’s Disease
06/04 08:00 am
GlobeNewswire Inc.
Read moreBetter High-Yield Dividend Stock to Buy: Bristol Myers Squibb or Pfizer?
06/04 02:30 am
The Motley Fool
Read moreLevicept to Present Data Suggesting LEVI-04 May Modify Disease in Osteoarthritis at EULAR 2026
06/03 04:00 am
GlobeNewswire Inc.
Read moreWhy Bristol Myers Squibb Stock Isn't Nearly As Cheap As It Looks
06/01 11:15 pm
The Motley Fool
Read moreAbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
06/01 02:19 pm
The Motley Fool
Read moreCRISPR Therapeutics' Secret Weapon That Many Investors Are Overlooking
06/01 12:30 pm
The Motley Fool
Read moreWhy Wall Street Is Dead Wrong About This Popular Stock
05/30 03:15 pm
The Motley Fool
Read moreBay Area Lyme Foundation Raises $900,000 at LymeAid 2026, Presenting Inaugural Neil L. Spector, MD, Legacy Award and $300,000 in Emerging Leader Grants
05/28 02:00 pm
GlobeNewswire Inc.
Read moreThis Healthcare Stock With 6%-Plus Yield: Is the Dividend Safe?
05/25 05:15 pm
The Motley Fool
Read moreTacrolimus Market Research Report 2026: Key Growth Drivers, Challenges, Future Opportunities, and Regulatory Landscape 2025-2035
05/25 05:31 am
GlobeNewswire Inc.
Read moreEli Lilly Just Made a Game-Changing Move in the Billion-Dollar Weight Loss Drug Space. Here's What You Need to Know.
05/25 05:05 am
The Motley Fool
Read moreIs Relay Therapeutics a Buy After Promising Trial Results?
05/22 05:30 pm
The Motley Fool
Read moreThe Most Important Healthcare Stock You're Not Watching
05/22 05:15 pm
The Motley Fool
Read moreThe Most Undervalued Healthcare Stock in the S&P 500 Right Now
05/21 07:05 am
The Motley Fool
Read moreESR1-Mutated Metastatic Breast Cancer Market Expected to Grow Rapidly at 9.6% CAGR During the Forecast Period (2026–2036) Due to the Emergence of Novel Oral SERDs and Targeted Agents | DelveInsight
05/20 01:00 pm
GlobeNewswire Inc.
Read morePfizer Expands Pneumococcal Vaccine Push With New Programs
05/20 09:14 am
Benzinga
Read morePulmonary Arterial Hypertension Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight
05/19 01:00 pm
GlobeNewswire Inc.
Read moreArbor Biotechnologies Appoints Mathew Pletcher, Ph.D., as Chief Scientific Officer
05/18 10:00 am
GlobeNewswire Inc.
Read more2 Ways to Play the Big Pharma Patent Cliff
05/15 10:18 am
Investing.com
Read moreMy Top 3 Healthcare Stocks for May 2026
05/15 08:33 am
The Motley Fool
Read moreWhy Doximity Stock Plunged Today
05/14 11:03 am
The Motley Fool
Read moreShould Eli Lilly Investors Worry About Its Newest Rival -- From Within?
05/14 05:05 am
The Motley Fool
Read moreGlobal Colorectal Cancer Diagnostics and Therapeutics Market Anticipates Impressive Growth Trajectory at a CAGR of ~9% by 2034 | DelveInsight
05/13 01:00 pm
GlobeNewswire Inc.
Read more3 Struggling Stocks That Could Make for Great Contrarian Buys
05/13 09:30 am
The Motley Fool
Read more